<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23931964</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1556-5653</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>100</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Fertility and sterility</Title>
          <ISOAbbreviation>Fertil Steril</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Using the ovarian sensitivity index to define poor, normal, and high response after controlled ovarian hyperstimulation in the long gonadotropin-releasing hormone-agonist protocol: suggestions for a new principle to solve an old problem.</ArticleTitle>
        <Pagination>
          <StartPage>1270</StartPage>
          <EndPage>1276</EndPage>
          <MedlinePgn>1270-6</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.fertnstert.2013.06.049</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0015-0282(13)00750-4</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To explore the utility of using the ratio between oocyte yield and total dose of FSH, i.e., the ovarian sensitivity index (OSI), to define ovarian response patterns.</AbstractText>
          <AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective cross-sectional study.</AbstractText>
          <AbstractText Label="SETTING" NlmCategory="METHODS">University-affiliated private center.</AbstractText>
          <AbstractText Label="PATIENT(S)" NlmCategory="METHODS">The entire unselected cohort of 7,520 IVF/intracytoplasmic sperm injection treatments (oocyte pick-ups [OPUs]) during an 8-year period (long GnRH agonist-recombinant FSH protocol).</AbstractText>
          <AbstractText Label="INTERVENTION(S)" NlmCategory="METHODS">None.</AbstractText>
          <AbstractText Label="MAIN OUTCOME MEASURE(S)" NlmCategory="METHODS">The distribution of the OSI (oocytes recovered × 1,000/total dose of FSH), the cutoff levels for poor and high response, set at ±1 SD, and the relationship between OSI and treatment outcome.</AbstractText>
          <AbstractText Label="RESULT(S)" NlmCategory="RESULTS">OSI showed a log-normal distribution with cutoff levels for poor and high response at 1.697/IU and 10.07/IU, respectively. A nomogram is presented. Live-birth rates per OPU were 10.5 ± 0.1%, 26.9 ± 0.6%, and 36.0 ± 1.4% for poor, normal, and high response treatments, respectively. The predictive power (C-statistic) for OSI to predict live birth was superior to that of oocyte yield.</AbstractText>
          <AbstractText Label="CONCLUSION(S)" NlmCategory="CONCLUSIONS">The OSI improves the definition of ovarian response patterns because it takes into account the degree of stimulation. The nomogram presents evidence-based cutoff levels for poor, normal, and high response and could be used for unifying study designs involving ovarian response patterns.</AbstractText>
          <CopyrightInformation>Copyright © 2013 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Huber</LastName>
            <ForeName>Malin</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Östersunds Sjukhus, Östersund, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hadziosmanovic</LastName>
            <ForeName>Nermin</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Berglund</LastName>
            <ForeName>Lars</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Holte</LastName>
            <ForeName>Jan</ForeName>
            <Initials>J</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Fertil Steril</MedlineTA>
        <NlmUniqueID>0372772</NlmUniqueID>
        <ISSNLinking>0015-0282</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006063">Chorionic Gonadotropin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005300">Fertility Agents, Female</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D043373">Follicle Stimulating Hormone, Human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1X0094V6JV</RegistryNumber>
          <NameOfSubstance UI="D017274">Nafarelin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>33515-09-2</RegistryNumber>
          <NameOfSubstance UI="D007987">Gonadotropin-Releasing Hormone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PXW8U3YXDV</RegistryNumber>
          <NameOfSubstance UI="D002064">Buserelin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002064" MajorTopicYN="N">Buserelin</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006063" MajorTopicYN="N">Chorionic Gonadotropin</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005300" MajorTopicYN="N">Fertility Agents, Female</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005307" MajorTopicYN="N">Fertilization in Vitro</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D043373" MajorTopicYN="N">Follicle Stimulating Hormone, Human</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007987" MajorTopicYN="N">Gonadotropin-Releasing Hormone</DescriptorName>
          <QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050498" MajorTopicYN="N">Live Birth</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017274" MajorTopicYN="N">Nafarelin</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049451" MajorTopicYN="N">Nomograms</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054315" MajorTopicYN="Y">Oocyte Retrieval</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016471" MajorTopicYN="N">Ovarian Hyperstimulation Syndrome</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010053" MajorTopicYN="N">Ovary</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010060" MajorTopicYN="N">Ovulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010062" MajorTopicYN="N">Ovulation Induction</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018873" MajorTopicYN="N">Pregnancy Rate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Controlled ovarian hyperstimulation</Keyword>
        <Keyword MajorTopicYN="N">cutoff levels</Keyword>
        <Keyword MajorTopicYN="N">excessive ovarian response</Keyword>
        <Keyword MajorTopicYN="N">ovarian sensitivity index</Keyword>
        <Keyword MajorTopicYN="N">poor ovarian response</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>1</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23931964</ArticleId>
        <ArticleId IdType="doi">10.1016/j.fertnstert.2013.06.049</ArticleId>
        <ArticleId IdType="pii">S0015-0282(13)00750-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
